June 10, 2024 03:24 PM EDT
R&D
Pharma

Paxlovid did not beat place­bo in Stan­ford-led long Covid study

Max Bayer

Pharma Reporter

Pfiz­er’s Covid-19 an­tivi­ral did not im­prove symp­toms in pa­tients with long Covid com­pared to place­bo — the lat­est dis­ap­point­ment for pa­tients with the post-in­fec­tion con­di­tion. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times